225528-11-0

Basic information

• Product Name: Fmoc-4-(2-methoxyphenyl)-L-phenylalanine
• Synonyms: Fmoc-4-(2-methoxyphenyl)-L-phenylalanine
• CAS NO: 225528-11-0
• Molecular Weight: 493.559
• Mol File: 225528-11-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Fmoc-4-(2-methoxyphenyl)-L-phenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: Fmoc-4-(2-methoxyphenyl)-L-phenylalanine(225528-11-0)
• EPA Substance Registry System: Fmoc-4-(2-methoxyphenyl)-L-phenylalanine(225528-11-0)

Safety Data

• Hazardous Substances Data: 225528-11-0(Hazardous Substances Data)

Upstream product

• 153037-34-4 (S)-2-t-butoxycarbonylamino-3-(2'-methoxy-biphenyl-4-yl)-propionic acid methyl ester 
• 112766-18-4 methyl N-(tert-butoxycarbonyl)-O-[(trifluoromethyl)sulfonyl]-L-tyrosinate 
• 4326-36-7 (S)-N-(tert-butoxycarbonyl)tyrosine methyl ester 
• 1080-06-4 L-Tyr-OMe 
• 60-18-4 L-tyrosine 
• 225528-05-2 N-Fmoc-(L)-4-iodophenylalanine t-butyl ester 
• 5720-06-9 2-Methoxyphenylboronic acid 
• 474542-80-8 N-Fmoc-(L)-4-(2'-methoxy)biphenylalanine t-butyl ester 

Relevant articles and documents

Synthesis and biological evaluation of tyrosine modified analogues of the α4β7 integrin inhibitor biotin-R8ERY

The α4β7 integrin is a well-known target for the development of drugs against various inflammatory disease states including inflammatory bowel disease, type 1 diabetes and multiple sclerosis. The synthesis of a small library of cell-permeable β7 integrin inhibitors based on the peptide biotin-R8ERY is reported, in which the tyrosine residue has been modified by using the Suzuki-Miyaura cross-coupling reaction. The synthesised peptidomimetics were evaluated in a cell adhesion assay and shown to inhibit Mn2+-activated adhesion of mouse TK-1 T cells to mouse MAdCAM-1. All of the synthesised peptidomimetics are more active than our previously reported lead compound biotin-R8ERY with two of the analogues, 6 and 7, exhibiting IC50 values of 15 μM.

Substituted ureas as cell adhesion inhibitors

Compounds of Formula I are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.